Namodenoson
drugOn this page
Also known as CF-102Cf102Chloro-ib-mecaCI-IB-MECACL-IB-MECASID26752072SID56463287
Summary
Namodenoson (CHEMBL431733) is a phase-3 clinical-stage small molecule targeting ADORA1, ADORA2A, and ADORA2B; indicated across 4 conditions including hepatocellular carcinoma and metabolic dysfunction-associated steatotic liver disease.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Targets: 4 (ADORA1, ADORA2A, ADORA2B…)
- Indications: 4 conditions
- Clinical trials: 6
- Chemistry: 544.7 Da · C18H18ClIN6O4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL431733 |
| Name | Namodenoson |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 3035850 |
| Molecular formula | C18H18ClIN6O4 |
| Molecular weight | 544.7 |
| InChIKey | IPSYPUKKXMNCNQ-PFHKOEEOSA-N |
SMILES: CNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)Cl)NCC4=CC(=CC=C4)I)O)O
IUPAC name: (2S,3S,4R,5R)-5-[2-chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide
Also known as: CF-102, Cf102, CF102, Chloro-ib-meca, CI-IB-MECA, CL-IB-MECA, Namodenoson, SID26752072, SID56463287, NAMODENOSON
Patent coverage: 277 distinct patent families (836 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 745 (89%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| ADORA1 | A1 receptor | Agonist | 6.66 | 0.3% | P30542 |
| ADORA2A | A2A receptor | Agonist | 5.27 | 0.4% | P29274 |
| ADORA2B | A2B receptor | Agonist | 5 | 0.5% | P29275 |
| ADORA3 | A3 receptor | Full agonist | 8.9 | 0% | P0DMS8 |
Broader ChEMBL bioactivity targets: 17 (assay-derived). Sample: Adenosine receptor A3, Ferritin light chain, 5-hydroxytryptamine receptor 2B, Adenosine receptor A2a, 5-hydroxytryptamine receptor 2C, Adenosine receptor A1, Peroxisome proliferator-activated receptor gamma, Adenosine receptor A2a, Adenosine receptor A3, Adenosine receptor A2a.
Bioactivity
ChEMBL activities: 129 potent at pChembl ≥ 5 of 132 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| Q61618 | 9.82 | EC50 | 0.15 | nM | CHEMBL_ACT_13377061 |
| Q61618 | 9.74 | Ki | 0.18 | nM | CHEMBL_ACT_2167198 |
| ADORA3 | 9.7 | Ki | 0.2 | nM | CHEMBL_ACT_18747717 |
| ADORA3 | 9.66 | Ki | 0.22 | nM | CHEMBL_ACT_10887385 |
| ADORA3 | 9.66 | Ki | 0.22 | nM | CHEMBL_ACT_13489785 |
| ADORA3 | 9.66 | Ki | 0.22 | nM | CHEMBL_ACT_1517275 |
| ADORA3 | 9.66 | Ki | 0.22 | nM | CHEMBL_ACT_1996071 |
| ADORA3 | 9.66 | Ki | 0.22 | nM | CHEMBL_ACT_2110353 |
| ADORA3 | 9.48 | Ki | 0.33 | nM | CHEMBL_ACT_117579 |
| P28647 | 9.48 | Ki | 0.33 | nM | CHEMBL_ACT_12139334 |
| ADORA3 | 9.48 | Ki | 0.33 | nM | CHEMBL_ACT_1473553 |
| P28647 | 9.48 | Ki | 0.33 | nM | CHEMBL_ACT_1518507 |
| P28647 | 9.48 | Ki | 0.33 | nM | CHEMBL_ACT_2167275 |
| P28647 | 9.48 | Ki | 0.33 | nM | CHEMBL_ACT_2374312 |
| P28647 | 9.48 | Ki | 0.33 | nM | CHEMBL_ACT_366161 |
| P28647 | 9.48 | Ki | 0.33 | nM | CHEMBL_ACT_642780 |
| P28647 | 9.48 | Ki | 0.33 | nM | CHEMBL_ACT_851731 |
| ADORA3 | 9.42 | Ki | 0.38 | nM | CHEMBL_ACT_2307144 |
| PPARD | 9.37 | Ki | 0.43 | nM | CHEMBL_ACT_18086685 |
| Q61618 | 9.34 | EC50 | 0.46 | nM | CHEMBL_ACT_16561841 |
| ADORA3 | 9.2 | Ki | 0.64 | nM | CHEMBL_ACT_1709927 |
| P28647 | 9.05 | Ki | 0.9 | nM | CHEMBL_ACT_792289 |
| ADORA3 | 9 | Ki | 1 | nM | CHEMBL_ACT_15045212 |
| ADORA3 | 9 | Ki | 1 | nM | CHEMBL_ACT_3087202 |
| ADORA3 | 9 | Ki | 1 | nM | CHEMBL_ACT_366160 |
| ADORA3 | 8.96 | Ki | 1.1 | nM | CHEMBL_ACT_1282223 |
| ADORA3 | 8.92 | IC50 | 1.21 | nM | CHEMBL_ACT_15045267 |
| ADORA3 | 8.92 | EC50 | 1.2 | nM | CHEMBL_ACT_2108220 |
| ADORA3 | 8.92 | EC50 | 1.21 | nM | CHEMBL_ACT_24348892 |
| ADORA3 | 8.85 | Ki | 1.4 | nM | CHEMBL_ACT_13398759 |
Target pathways
Aggregated over 4 target gene(s): ADORA1, ADORA2A, ADORA2B, ADORA3.
Top Reactome pathways
23 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Signal Transduction | 4 | ADORA1, ADORA2A, ADORA2B, ADORA3 |
| Signaling by GPCR | 4 | ADORA1, ADORA2A, ADORA2B, ADORA3 |
| Class A/1 (Rhodopsin-like receptors) | 4 | ADORA1, ADORA2A, ADORA2B, ADORA3 |
| GPCR downstream signalling | 4 | ADORA1, ADORA2A, ADORA2B, ADORA3 |
| Adenosine P1 receptors | 4 | ADORA1, ADORA2A, ADORA2B, ADORA3 |
| Nucleotide-like (purinergic) receptors | 4 | ADORA1, ADORA2A, ADORA2B, ADORA3 |
| GPCR ligand binding | 4 | ADORA1, ADORA2A, ADORA2B, ADORA3 |
| Metabolism of proteins | 2 | ADORA2A, ADORA2B |
| G alpha (s) signalling events | 2 | ADORA2A, ADORA2B |
| G alpha (i) signalling events | 2 | ADORA1, ADORA3 |
| Surfactant metabolism | 2 | ADORA2A, ADORA2B |
| Disease | 1 | ADORA2B |
| Signaling by NTRKs | 1 | ADORA2A |
| Activation of TRKA receptors | 1 | ADORA2A |
| NGF-independant TRKA activation | 1 | ADORA2A |
| Signaling by NTRK1 (TRKA) | 1 | ADORA2A |
| Infectious disease | 1 | ADORA2B |
| Signaling by Receptor Tyrosine Kinases | 1 | ADORA2A |
| Leishmania infection | 1 | ADORA2B |
| ADORA2B mediated anti-inflammatory cytokines production | 1 | ADORA2B |
| Anti-inflammatory response favouring Leishmania parasite infection | 1 | ADORA2B |
| Leishmania parasite growth and survival | 1 | ADORA2B |
| Parasitic Infection Pathways | 1 | ADORA2B |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| signal transduction | 4 |
| G protein-coupled receptor signaling pathway | 4 |
| G protein-coupled adenosine receptor signaling pathway | 4 |
| inflammatory response | 3 |
| negative regulation of cell population proliferation | 3 |
| vasodilation | 3 |
| presynaptic modulation of chemical synaptic transmission | 3 |
| phagocytosis | 2 |
| cell-cell signaling | 2 |
| response to purine-containing compound | 2 |
| excitatory postsynaptic potential | 2 |
| apoptotic signaling pathway | 2 |
| negative regulation of inflammatory response | 2 |
| adenylate cyclase-activating G protein-coupled receptor signaling pathway | 2 |
| regulation of norepinephrine secretion | 2 |
Indications & clinical
Indications
4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| hepatocellular carcinoma | 2 | MONDO:0007256 | EFO:0000182 |
| metabolic dysfunction-associated steatotic liver disease | 2 | MONDO:0013209 | EFO:0003095 |
| metabolic dysfunction-associated steatohepatitis | 2 | MONDO:0007027 | EFO:1001249 |
| chronic hepatitis C virus infection | 1 | MONDO:0005354 | EFO:0004220 |
Clinical trials
Total trials: 6.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 4 |
| PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05201404 | PHASE3 | RECRUITING | Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis |
| NCT04697810 | PHASE2 | RECRUITING | Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH) |
| NCT06387342 | PHASE2 | RECRUITING | Namodenoson Treatment of Advanced Pancreatic Cancer |
| NCT00790218 | PHASE1/PHASE2 | COMPLETED | A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma |
| NCT02128958 | PHASE2 | COMPLETED | Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) |
| NCT02927314 | PHASE2 | COMPLETED | A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
476 molecules share ≥1 primary target. Top 60 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| ADENOSINE | ChEMBL | Phase 4 (approved) | ADORA1, ADORA2A, ADORA2B, ADORA3 |
| CAFFEINE | ChEMBL | Phase 4 (approved) | ADORA1, ADORA2A, ADORA2B, ADORA3 |
| ISTRADEFYLLINE | ChEMBL | Phase 4 (approved) | ADORA1, ADORA2A, ADORA2B, ADORA3 |
| REGADENOSON | ChEMBL | Phase 4 (approved) | ADORA1, ADORA2A, ADORA2B, ADORA3 |
| THEOPHYLLINE | ChEMBL | Phase 4 (approved) | ADORA1, ADORA2A, ADORA2B, ADORA3 |
| BINODENOSON | ChEMBL | Phase 3 | ADORA1, ADORA2A, ADORA2B, ADORA3 |
| ROLOFYLLINE | ChEMBL | Phase 3 | ADORA1, ADORA2A, ADORA2B, ADORA3 |
| TONAPOFYLLINE | ChEMBL | Phase 3 | ADORA1, ADORA2A, ADORA2B, ADORA3 |
| TOZADENANT | ChEMBL | Phase 3 | ADORA1, ADORA2A, ADORA2B, ADORA3 |
| TRABODENOSON | ChEMBL | Phase 3 | ADORA1, ADORA2A, ADORA2B, ADORA3 |
| CIFORADENANT | ChEMBL | Phase 2 | ADORA1, ADORA2A, ADORA2B, ADORA3 |
| DERENOFYLLINE | ChEMBL | Phase 2 | ADORA1, ADORA2A, ADORA2B, ADORA3 |
| ENPROFYLLINE | ChEMBL | Phase 2 | ADORA1, ADORA2A, ADORA2B, ADORA3 |
| IMARADENANT | ChEMBL | Phase 2 | ADORA1, ADORA2A, ADORA2B, ADORA3 |
| TECADENOSON | ChEMBL | Phase 2 | ADORA1, ADORA2A, ADORA2B, ADORA3 |
| VIPADENANT | ChEMBL | Phase 2 | ADORA1, ADORA2A, ADORA2B, ADORA3 |
| Fidaxomicin | ChEMBL + PubChem | Phase 4 (approved) | ADORA1, ADORA2A, ADORA3 |
| Linagliptin | ChEMBL + PubChem | Phase 4 (approved) | ADORA1, ADORA2A, ADORA3 |
| Pyrazinamide | ChEMBL + PubChem | Phase 4 (approved) | ADORA1, ADORA2A, ADORA3 |
| CLOFARABINE | ChEMBL | Phase 4 (approved) | ADORA1, ADORA2A, ADORA3 |
| CLOTRIMAZOLE | ChEMBL | Phase 4 (approved) | ADORA1, ADORA2A, ADORA3 |
| DIETHYLSTILBESTROL | ChEMBL | Phase 4 (approved) | ADORA1, ADORA2A, ADORA3 |
| ECONAZOLE | ChEMBL | Phase 4 (approved) | ADORA1, ADORA2A, ADORA3 |
| EPALRESTAT | ChEMBL | Phase 4 (approved) | ADORA1, ADORA2A, ADORA3 |
| FEDRATINIB | ChEMBL | Phase 4 (approved) | ADORA1, ADORA2A, ADORA3 |
| MEFLOQUINE | ChEMBL | Phase 4 (approved) | ADORA1, ADORA2A, ADORA3 |
| MICONAZOLE | ChEMBL | Phase 4 (approved) | ADORA1, ADORA2A, ADORA3 |
| NEVIRAPINE | ChEMBL | Phase 4 (approved) | ADORA1, ADORA2A, ADORA3 |
| NIFEDIPINE | ChEMBL | Phase 4 (approved) | ADORA1, ADORA2A, ADORA3 |
| NIMESULIDE | ChEMBL | Phase 4 (approved) | ADORA1, ADORA2A, ADORA3 |
| NISOLDIPINE | ChEMBL | Phase 4 (approved) | ADORA1, ADORA2A, ADORA3 |
| NITAZOXANIDE | ChEMBL | Phase 4 (approved) | ADORA1, ADORA2A, ADORA3 |
| PENTOSTATIN | ChEMBL | Phase 4 (approved) | ADORA1, ADORA2A, ADORA3 |
| PYRVINIUM | ChEMBL | Phase 4 (approved) | ADORA1, ADORA2A, ADORA3 |
| RIFAMPIN | ChEMBL | Phase 4 (approved) | ADORA1, ADORA2A, ADORA3 |
| RIFAXIMIN | ChEMBL | Phase 4 (approved) | ADORA1, ADORA2A, ADORA3 |
| SUNITINIB | ChEMBL | Phase 4 (approved) | ADORA1, ADORA2A, ADORA3 |
| TAMOXIFEN | ChEMBL | Phase 4 (approved) | ADORA1, ADORA2A, ADORA3 |
| APADENOSON | ChEMBL | Phase 3 | ADORA1, ADORA2A, ADORA3 |
| DIACEREIN | ChEMBL | Phase 3 | ADORA1, ADORA2A, ADORA3 |
| ETRUMADENANT | ChEMBL | Phase 2 | ADORA1, ADORA2A, ADORA2B |
| METRIFUDIL | ChEMBL | Phase 2 | ADORA1, ADORA2A, ADORA3 |
| SONEDENOSON | ChEMBL | Phase 2 | ADORA1, ADORA2A, ADORA2B |
| TOFIMILAST | ChEMBL | Phase 2 | ADORA1, ADORA2A, ADORA3 |
| Afatinib | PubChem | Approved | ADORA1, ADORA2A, ADORA3 |
| Apixaban | PubChem | Approved | ADORA1, ADORA2A, ADORA3 |
| Binimetinib | PubChem | Approved | ADORA1, ADORA2A, ADORA3 |
| Bosentan | PubChem | Approved | ADORA1, ADORA2A, ADORA3 |
| chenodiol | PubChem | Approved | ADORA1, ADORA2A, ADORA3 |
| Dihydroergotamine | PubChem | Approved | ADORA1, ADORA2A, ADORA3 |
| Fulvestrant | PubChem | Approved | ADORA1, ADORA2A, ADORA3 |
| Imipenem | PubChem | Approved | ADORA1, ADORA2A, ADORA3 |
| Propoxyphene | PubChem | Approved | ADORA1, ADORA2A, ADORA3 |
| ALPIDEM | ChEMBL | Phase 4 (approved) | ADORA1, ADORA3 |
| AMPHETAMINE | ChEMBL | Phase 4 (approved) | ADORA1, ADORA2A |
| BALSALAZIDE | ChEMBL | Phase 4 (approved) | ADORA2A, ADORA3 |
| BITHIONOL | ChEMBL | Phase 4 (approved) | ADORA2A, ADORA3 |
| DAUNORUBICIN | ChEMBL | Phase 4 (approved) | ADORA2A, ADORA3 |
| ENASIDENIB | ChEMBL | Phase 4 (approved) | ADORA1, ADORA3 |
| ERLOTINIB | ChEMBL | Phase 4 (approved) | ADORA2A, ADORA3 |
Related Atlas pages
- Genes: ADORA1, ADORA2A, ADORA2B, ADORA3
- Drugs: Adenosine, Caffeine, Istradefylline, Regadenoson, Theophylline, Binodenoson, Rolofylline, Tonapofylline, Tozadenant, Trabodenoson, Fidaxomicin, Linagliptin, Pyrazinamide, Clofarabine, Clotrimazole, Diethylstilbestrol, Econazole, Epalrestat, Fedratinib, Mefloquine, Miconazole, Nevirapine, Nifedipine, Nimesulide, Nisoldipine, Nitazoxanide, Pentostatin, Pyrvinium, Rifampin, Rifaximin, Sunitinib, Tamoxifen, Apadenoson, Diacerein, Afatinib, Apixaban, Binimetinib, Bosentan, chenodiol, Dihydroergotamine, Fulvestrant, Imipenem, Propoxyphene, Alpidem, Amphetamine, Balsalazide, Bithionol, Daunorubicin, Enasidenib, Erlotinib